Mayo Clinic: Multiple Myeloma trials

The registry lists 83 Multiple Myeloma studies with Mayo Clinic as lead sponsor. 11 are open to participants now and 41 have results posted.

Phase 1 32Phase 2 53Phase 3 4No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersRecruitingNCT07850284
• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06940297Phase 2
• Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingNCT06785415Phase 1/2
• Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)RecruitingNCT06630104Not applicable
• Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
• Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple MyelomaRecruitingNCT06145581Not applicable
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerRecruitingNCT05969860Phase 2
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaRecruitingNCT05847569Phase 2
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• Family Study of Lymphoproliferative DisordersRecruitingNCT00626496
• Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT StudyCompletedNCT06063603Not applicableResults posted
• Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
• Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedNCT03713294Phase 2Results posted
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted
• Daratumumab in Treating Transplant-Eligible Patients With Multiple MyelomaCompletedNCT03477539Phase 2Results posted
• Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaCompletedNCT03202628Phase 2Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results posted
• Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02633059Phase 1/2Results posted
• Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCTTerminatedNCT02619812Phase 2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple MyelomaCompletedNCT02492750Phase 1Results posted
• Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02086552Phase 2Results posted
• SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01955434Phase 2Results posted
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisCompletedNCT01864018Phase 1/2Results posted
• Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01842308Phase 1/2Results posted
• Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideCompletedNCT01794039Phase 2Results posted
• Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell TransplantCompletedNCT01706666Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01646762Phase 2Results posted
• Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibCompletedNCT01415882Phase 2Results posted
• Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01212952Phase 1/2Results posted
• Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple MyelomaCompletedNCT01057225Phase 1/2Results posted
• Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01049945Phase 1/2Results posted
• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01034553Phase 1/2Results posted
• Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantCompletedNCT00998049Phase 2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
• Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple MyelomaCompletedNCT00635154Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00478218Phase 2Results posted
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00450814Phase 1/2Results posted
• Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple MyelomaCompletedNCT00432458Phase 3Results posted
• Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaTerminatedNCT07045727Not applicable
• A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple MyelomaCompletedNCT06151717
• MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple MyelomaActive, not recruitingNCT06042725Phase 1
• Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple MyelomaCompletedNCT05918185
• Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
• Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT05411497Phase 1
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
• Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT StudyCompletedNCT05053100
• Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaTerminatedNCT04892264Phase 1
• Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma PatientsCompletedNCT04783038Not applicable
• Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE TrialActive, not recruitingNCT04764942Phase 1/2
• Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
• Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03829020Phase 1
• Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaCompletedNCT03399539Phase 1
• Dysregulation of Glutamine Activity in the Pathogenesis of Multiple MyelomaCompletedNCT03119883Not applicable
• Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
• Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedNCT02697344Phase 1
• Novel Support Options in Autologous Stem Cell Transplant for Multiple MyelomaCompletedNCT02274519Not applicable
• Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
• Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantWithdrawnNCT01812720Phase 2
• Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT00995059Phase 1/2
• Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
• Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00616720Phase 2
• Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantCompletedNCT00602706Phase 1/2
• Bevacizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00482495Phase 2
• Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainCompletedNCT00482378Phase 1/2
• Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
• PS-341 in Treating Patients With Advanced CancerCompletedNCT00006362Phase 1
• Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple MyelomaCompletedNCT00006219Phase 2
• High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First RelapseCompletedNCT00002630Phase 2